Search results
Results from the WOW.Com Content Network
TOKYO (Reuters) -Drugmaker Merck will pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs, they said, in a deal that could be worth up to $22 billion to the ...
The treatment is one of three antibody-drug conjugates (ADCs) included in Merck's up to $22-billion joint development and commercialization deal with Daiichi Sankyo, signed last year.
Trastuzumab deruxtecan is indicated for the treatment of adults with unresectable (unable to be removed with surgery) or metastatic (when cancer cells spread to other parts of the body) HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting and for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal ...
Ifinatamab deruxtecan (DS-7300) is an experimental anti-cancer treatment developed by Merck and Daiichi Sankyo. It is an antibody–drug conjugate that "consists of an anti-B7-H3 antibody linked with a DNA topoisomerase I inhibiting anti-tumor agent". [1] [2]
AstraZeneca Plc (NASDAQ: AZN) and Daiichi Sankyo (OTC: DSNKY) announced detailed results from the positive DESTINY-Gastric02 Phase 2 trial of Enhertu (fam-trastuzumab deruxtecan-nxki). The trial ...
In 2019 AstraZeneca agreed to pay up to US$6.9 billion to jointly develop DS-8201 with Japan's Daiichi Sankyo. It is intended to replace Herceptin for treating breast cancer. DS8201 carries eight payloads, compared to the usual four. [2]
AstraZeneca said on Monday its cancer drug, Enhertu, developed with Japan's Daiichi Sankyo delayed the progression of a form of advanced breast cancer in previously treated patients, boosting ...
Daiichi Sankyo: granted for three indications: HER2-positive breast cancer with prior anti-HER2-based treatment; HER2 low (IHC 1+ or IHC 2+/ISH) breast cancer; and non-small cell lung cancer with an activating HER2 mutation Dupilumab: Regeneron Pharmaceuticals: granted for two indications: eosinophilic esophagitis; and atopic dermatitis: Ivosidenib